Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model

Renal Failure

Volumn 33, Issue 3, 2011, Pages 355-362

  Chunming, Jiang ^a   Miao, Zhang ^a   Cheng, Sun ^a   Nana, Tao ^a   Wei, Zhu ^a   Dongwei, Cao ^a   Yuan, Feng ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

connective tissue growth factor; Peritoneal fibrosis; Tanshinone IIA; transforming growth factor b1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; PERITONEAL DIALYSIS FLUID; TANSHINONE IIA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; LOW DRUG DOSE; MALE; MESOTHELIUM; NONHUMAN; OMENTUM; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONNECTIVE TISSUE GROWTH FACTOR; DITERPENES, ABIETANE; DRUGS, CHINESE HERBAL; IMMUNOHISTOCHEMISTRY; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79952674320     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.559681     Document Type: Article

References (37)

1. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int. 2000;20(Suppl. 3):S5-S96.
2. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int. 1999;55:341-356. (Pubitemid 29004273)
3. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470-479. (Pubitemid 34106290)
4. Ito T, Yorioka N. Peritoneal damage by peritoneal dialysis solutions. Clin Exp Nephrol. 2008;12:243-249.
5. Gonzalez-Mateo GT, Loureiro J, Jimenez-Hefferman JA, et al. Chronic exposure of mouse peritoneum to peritoneal dialysis fluid: Structural and functional alterations of the peritoneal membrane. Perit Dial Int. 2009;29:227-230.
6. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dial-ysis solutions on the secretion of growth factors and extracellu-lar matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002;22:171-177. (Pubitemid 34546327)
7. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292. (Pubitemid 24333194)
8. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol. 1996;7:2495-2508. (Pubitemid 27469555)
9. Rougier JP, Guia S, Hagege J, Nguyen G, Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothe-lial cell cultures: Transcriptional regulation by TGF-beta 1. Kidney Int. 1998;54:87-98. (Pubitemid 28288023)
10. Martin J, Yung S, Robson RL, Steadman R, Davies M. Pro-duction and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int. 2000;20:524-533.
11. Yung S, Chen XR, Tsang RC, Zhang Q, Chan TM. Reduc-tion of perlecan synthesis and induction of TGF-beta1 in human peritoneal mesothelial cells due to high dialysate glu-cose concentration: Implication in peritoneal dialysis. J Am Soc Nephrol. 2004;15:1178-1188. (Pubitemid 38525999)
12. Naiki Y, Maeda Y, Matsuo K, et al. Involvement of TGF-beta signal for peritoneal sclerosing in continuous ambulatory peri-toneal dialysis. J Nephrol. 2003;16:95-102.
13. Ha H, Yu MR, Lee HB. High glucose-induced PKC activa-tion mediates TGF-beta 1 and fibronectin synthesis by perito-neal mesothelial cells. Kidney Int. 2001;59:463-470. (Pubitemid 32157911)
14. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gaul-die J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol. 2001;12:2029-2039. (Pubitemid 32880339)
15. Zarrinkalam KH, Stanley JM, Gray J, Oliver N, Faull RJ. Connective tissue growth factor and its regulation in the peri-toneal cavity of peritoneal dialysis patients. Kidney Int. 2003;64:331-338. (Pubitemid 36714188)
16. Sakamoto N, Sugimura K, Kawashima H, et al. Influence of glucose and inflammatory cytokines on TGF-beta1 and CTGF mRNA expressions in human peritoneal mesothelial cells. Int J Mol Med. 2005;15:907-911.
17. Szeto CC, Lai KB, Chow KM, Szeto CY, Wong TY, Li PK. Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell. Neph-ron Exp Nephrol. 2005;99:e95-e104.
18. Mizutani M, Ito Y, Mizuno M, et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Phys-iol Renal Physiol. 2010;298:F721-F733.
19. Xiao L, Sun L, Liu FY, Peng YM, Duan SB. Connective tissue growth factor knockdown attenuated matrix protein production and vascular endothelial growth factor expression induced by transforming growth factor-beta1 in cultured human peritoneal mesothelial cells. Ther Apher Dial. 2010;14:27-34.
20. Liu T, Jin H, Sun QR, Xu JH, Hu HT. The neuroprotective effects of tanshinone IIA on beta-amyloid-induced toxicity in rat cortical neurons. Neuropharmacology. 2010;59:595-604.
21. Yang L, Zou XJ, Gao X, et al. Sodium tanshinone IIA sul-fonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med. 2009;41:508-516.
22. Li YI, Elmer G, Leboeuf RC. Tanshinone IIA reduces mac-rophage death induced by hydrogen peroxide by upregulating glutathione peroxidase. Life Sci. 2008;83:557-562.
23. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 2007;568:213-221. (Pubitemid 46976900)
24. Tang F, Wu X, Wang T, et al. Tanshinone IIA attenuates ath-erosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol. 2007;46:427-438. (Pubitemid 46552282)
25. Honda K, Hamada C, Nakayama M, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: A quantitative study of peritoneal mem-brane morphology. Clin J Am Soc Nephrol. 2008;3:720-728.
26. Selgas R, Fernandez-Reyes MJ, Bosque E, et al. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis. 1994;23:64-73. (Pubitemid 24021750)
27. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peri-toneal dialysis? Kidney Int. 1998;54:2207-2217. (Pubitemid 28533651)
28. Kihm LP, Wibisono D, Muller-Krebs S, et al. Rage expression in the human peritoneal membrane. Nephrol Dial Transplant. 2008;23:3302-3306.
29. Matsuo K, Maeda Y, Naiki Y, et al. Possible effects of hepato-cyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp Nephrol. 2005;99:e87-e94.
30. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol. 2005;16:144-150. (Pubitemid 43073166)
31. Zareie M, Tangelder GJ, Ter Wee PM, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant. 2005;20:2783-2792. (Pubitemid 41672280)
32. Lee EA, Oh JH, Lee HA, et al. Structural and functional alter-ations of the peritoneum after prolonged exposure to dialysis solutions: Role of aminoguanidine. Perit Dial Int. 2001;21:245-253. (Pubitemid 32734431)
33. Fang J, Xu SW, Wang P, et al. Tanshinone IIA attenuates car-diac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine. 2010;18:58-64.
34. Sun RF, Liu LX, Zhang HY. Effect of Tanshinone II on hepatic fibrosis in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009;29:1012-1017.
35. Tang J, Zhan C, Zhou J. Effects of Tanshinone IIA on trans-forming growth factor beta1-Smads signal pathway in renal interstitial fibroblasts of rats. J Huazhong Univ Sci Technol Med Sci. 2008;28:539-542.
36. Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tan-shen. Med Res Rev. 2007;27:133-148. (Pubitemid 44975189)
37. Zhou L, Zuo Z, Chow MS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345-1359. (Pubitemid 41643896)